683a1606c782e11e38d1b140
3094
AST to Platelet Ratio Index (APRI)
AST to Platelet Ratio Index (APRI)
APRI
Determines the likelihood of hepatic fibrosis and cirrhosis in patients with hepatitis C.
Predicts hepatitis C-related hepatic fibrosis and cirrhosis.
ast-platelet-ratio-index-apri
The AST to Platelet Ratio Index (APRI) determines the likelihood of hepatic fibrosis and cirrhosis in patients with Hepatitis C.
lin, apri, ast, platelet, cirrhosis, hep c, fibrosis, plt, amino, apri score, ast to platelet ratio index
[ "Abdominal Pain" ]
APRI = (AST in IU/L) / (AST Upper Limit of Normal in IU/L) / (Platelets in 109/L)
[ { "name": "Aspartate Aminotransferase", "unit": "AST", "error_min": "1", "error_max": "10000", "warn_min": "4", "warn_max": "4000", "conversion": "1", "normal_max_si": "41", "normal_max_us": "41", "normal_min_si": "15", "normal_min_us": "15", "units_si": "U/L", "units_us": "U/L" }, { "name": "Platelet Count", "unit": "plt", "error_min": "1", "error_max": "3200", "warn_min": "10", "warn_max": "750", "conversion": "1", "normal_max_si": "350", "normal_max_us": "350", "normal_min_si": "150", "normal_min_us": "150", "units_si": "× 10⁹/L", "units_us": "× 10³/µL" } ]
Based on 2011 meta-analysis in Hepatology by Lin et. al:
Significant fibrosis: APRI threshold of 0.7 was 77% sensitive and 72% specific.
Severe fibrosis: APRI threshold of 1.0 was 61% sensitive and 64% specific.
Cirrhosis: APRI threshold of 1.0 was 76% sensitive and 72% specific.
{ "Clinical Practice Guidelines": [ { "href": "", "text": "" } ], "Manufacturer Website": [ { "href": "", "text": "" } ], "Original/Primary Reference": [ { "href": "https://www.ncbi.nlm.nih.gov/pubmed/12883497", "text": "Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26." } ], "Other References": [ { "href": "https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2011.04897.x/full", "text": "Sebastiani G, Halfon P, Castera L, et al. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther. 2012;35(1):92-104." } ], "Outcomes": [ { "href": "", "text": "" } ], "Validation": [ { "href": "https://www.ncbi.nlm.nih.gov/pubmed/19999223", "text": "Khan DA, Fatima Tuz Z, Khan FA, Mubarak A. Evaluation of diagnostic accuracy of APRI for prediction of fibrosis in hepatitis C patients. J Ayub Med Coll Abbottabad 2008; 20: 122-126." }, { "href": "https://onlinelibrary.wiley.com/doi/10.1002/hep.24105/abstract", "text": "Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-36." } ], "Validations": [] }
Points to keep in mind:
Patients with hepatitis C being considered for liver biopsy to determine chance of fibrosis or cirrhosis.
There is no perfect method for predicting fibrosis and cirrhosis in HCV and the APRI uses commonly available laboratory values that may help avoid the need for liver biopsy. The FIB-4 Score may also be useful in these patients as well.
This index is among the best validated methods for predicting HCV progression. At extreme values (very high or very low) the APRI can avoid further invasive testing in a substantial proportion of patients. Unfortunately, findings in validation studies suggest only moderate predictive value.
The APRI is validated in HCV referral populations, thus extending it to other conditions or populations may be misleading. Upper reference values for AST vary by laboratory, which can also significantly affect results.
We are unaware of validated management algorithms using the APRI.
[ "Hepatitis" ]
{ "conditionality": "", "default": null, "fhir_rules": null, "inct": null, "label_en": "AST", "name": "ast", "optional": false, "tips_en": "", "type": "textbox", "unit": "AST" }
{ "conditionality": "", "default": 40, "fhir_rules": null, "inct": null, "label_en": "AST upper limit of normal", "name": "uln", "optional": false, "tips_en": "", "type": "textbox", "unit": "AST" }
{ "conditionality": "", "default": null, "fhir_rules": null, "inct": null, "label_en": "Platelet count", "name": "plt", "optional": false, "tips_en": "", "type": "textbox", "unit": "plt" }
[ { "conditionality": "", "default": null, "fhir_rules": null, "inct": null, "label_en": "AST", "name": "ast", "optional": false, "tips_en": "", "type": "textbox", "unit": "AST" }, { "conditionality": "", "default": 40, "fhir_rules": null, "inct": null, "label_en": "AST upper limit of normal", "name": "uln", "optional": false, "tips_en": "", "type": "textbox", "unit": "AST" }, { "conditionality": "", "default": null, "fhir_rules": null, "inct": null, "label_en": "Platelet count", "name": "plt", "optional": false, "tips_en": "", "type": "textbox", "unit": "plt" } ]
2022-04-21T20:29:12.374Z
[ "Formula" ]
[ "cirrhosis", "hep c", "fibrosis", "plt", "amino" ]
{ "keywords_en": "lin, apri, ast, platelet, cirrhosis, hep c, fibrosis, plt, amino, apri score, ast to platelet ratio index", "meta_description_en": "The AST to Platelet Ratio Index (APRI) determines the likelihood of hepatic fibrosis and cirrhosis in patients with Hepatitis C." }
[ "Gastroenterology", "Hepatology", "Internal Medicine" ]
[ "Gastrointestinal" ]
[]
1
[]
[ { "calcId": 3081, "short_title_en": "NAFLD Fibrosis Score", "slug": "nafld-non-alcoholic-fatty-liver-disease-fibrosis-score" }, { "calcId": 2200, "short_title_en": "FIB-4 Index", "slug": "fibrosis-4-fib-4-index-liver-fibrosis" }, { "calcId": 78, "short_title_en": "MELD Na (UNOS/OPTN)", "slug": "meld-score-model-end-stage-liver-disease-12-older" } ]
false
[ "whenToUseViewed", "pearlsPitfallsViewed", "whyUseViewed", "nextStepsViewed", "evidenceViewed" ]
[ "gastroenterology" ]
[ "Patients with hepatitis C being considered for liver biopsy to determine chance of fibrosis or cirrhosis." ]
false